Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
5 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to NewcelX Ltd.’s names, not what it holds today.
Patents granted
5
5 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against none in 2024 and 2 in 2023
Applications published
20
3 of them in 2025
Names they are printed under
4
a subsidiary, a former name
By yearGrantedApplications published
'14'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Kadimastem Ltd. a subsidiary
IL, as the owner printed on each patent
6 publishedNLS Pharmaceutics AG a former name
CH, as the owner printed on each patent
5 publishedNLS PHARMACEUTICS AG a former name
named as the applicant on its applications, in CH
6 publishedKadimastem Ltd. a subsidiary
named as the applicant on its applications, in IL
3 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jun 20, 2023 | 11,679,133 | Methods for differentiating and purifying pancreatic endocrine cells | Pharmaceuticals | Kadimastem Ltd. |
| Mar 7, 2023 | 11,596,622 | Mazindol treatment for heroin dependence and substance use disorder | Pharmaceuticals | NLS Pharmaceutics AG |
| Dec 28, 2021 | 11,207,271 | Mazindol IR/SR multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (ADHD) | Pharmaceuticals | NLS Pharmaceutics AG |
| Oct 29, 2019 | 10,456,387 | Phacetoperane for treating of attention deficit hyperactivity disorder | Pharmaceuticals | NLS Pharmaceutics AG |
| Aug 2, 2016 | 9,404,087 | Insulin producing cells derived from pluripotent stem cells | Biotechnology | Kadimastem Ltd. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Aug 28, 2025 | 2025/0268859 | OXAFURAMINE, (1R)-N-ETHYL-1-[(2R)-OXOLAN-2-YL]-2-PHENYLETHANAMINE, HYDROCHLORIDE AND DERIVATIVES THEREOF FOR TREATING ALZHEIMER'S DISEASE (AD), VASCULAR DEMENTIA, DEMENTIA WITH LEWY BODIES (DLB), MIXED DEMENTIA, FRONTOTEMPORAL LOBAR DEGENERATION (FTLD), AND PARKINSON'S DISEASE (PD) | Pharmaceuticals | NLS Pharmaceutics AG |
| Mar 13, 2025 | 2025/0082598 | Melafenoxate, 2-(1-adamantylamino)ethyl 2-(4-chlorophenoxy)acetate and derivatives thereof for treating circadian rhythm sleep disorders with neurodegenerative diseases such as Alzheimer's disease | Pharmaceuticals | NLS Pharmaceutics AG |
| Feb 13, 2025 | 2025/0049737 | Lauflumide and derivatives thereof for treating chronic fatigue syndrome and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) | Pharmaceuticals | NLS Pharmaceutics AG |
| Sep 26, 2024 | 2024/0316023 | BENEDIN, PIPERIDINE, 2-BENZHYDRYL-3-HYDROXY-N-METHYL-, HYDROCHLORIDE AND DERIVATIVES THEREOF FOR USE IN TREATING KLEINE-LEVIN SYNDROME | Pharmaceuticals | NLS Pharmaceutics AG |
| May 23, 2024 | 2024/0165034 | MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) | Pharmaceuticals | NLS PHARMACEUTICS AG |
| Apr 4, 2024 | 2024/0108605 | MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY | Pharmaceuticals | NLS PHARMACEUTICS AG |
| Aug 10, 2023 | 2023/0248779 | METHODS FOR DIFFERENTIATING AND PURIFYING PANCREATIC ENDOCRINE CELLS | Pharmaceuticals | Kadimastem Ltd. |
| Dec 8, 2022 | 2022/0387514 | METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME | Pharmaceuticals | Kadimastem Ltd. |
| May 26, 2022 | 2022/0160639 | MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) | Pharmaceuticals | NLS PHARMACEUTICS AG |
| Feb 24, 2022 | 2022/0054471 | PHACETOPERANE FOR TREATING OF ATTENTION DEFICIT HYPERACTIVITY DISORDER | Pharmaceuticals | NLS PHARMACEUTICS AG |
What it applied for, 2024 to 2025: Pharmaceuticals 6.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.